| [1] |
Zhao Z, Liu W. Pancreatic cancer: a review of risk factors, diagnosis, and treatment[J]. Technol Cancer Res Treat, 2020, 19: 1533033820 962117. DOI: 10.1177/1533033820962117.
|
| [2] |
Stoffel EM, Brand RE, Goggins M. Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention[J]. Gastroenterology, 2023, 164(5): 752-765. DOI: 10.1053/j.gastro.2023.02.012.
pmid: 36804602
|
| [3] |
中国医师协会临床精准医疗专业委员会, 中国抗癌协会肿瘤胰腺病学专业委员会. 早期胰腺癌分子诊断专家共识 (2023年版)[J]. 临床肝胆病杂志, 2024, 40(3): 473-477. DOI: 10.12449/JCH240306.
|
| [4] |
张洪义, 邢颖. 胰腺恶性肿瘤综合治疗现状[J]. 中国临床医生杂志, 2023, 51(6): 631-633. DOI: 10.3969/j.issn.2095-8552.2023.06.001.
|
| [5] |
Domagała-Haduch M, Gorzelak-Magiera A, Michalecki Ł, et al. Radiochemotherapy in pancreatic cancer[J]. Curr Oncol, 2024, 31(6): 3291-3300. DOI: 10.3390/curroncol31060250.
pmid: 38920733
|
| [6] |
Park W, Chawla A, O'Reilly EM. Pancreatic cancer: a review[J]. JAMA, 2021, 326(9): 851-862. DOI: 10.1001/jama.2021.13027.
pmid: 34547082
|
| [7] |
Zheng R, Liu X, Zhang Y, et al. Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application[J]. Front Immunol, 2024, 15: 1383978. DOI: 10.3389/fimmu.2024.1383978.
|
| [8] |
Liu L, Huang X, Shi F, et al. Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy[J]. J Exp Clin Cancer Res, 2022, 41(1): 56. DOI: 10.1186/s13046-022-02273-w.
|
| [9] |
Wainberg ZA, Hochster HS, Kim EJ, et al. Open-label, phase Ⅰ study of nivolumab combined with nab-paclitaxel plus gemcitabine in advanced pancreatic cancer[J]. Clin Cancer Res, 2020, 26(18): 4814-4822. DOI: 10.1158/1078-0432.Ccr-20-0099.
pmid: 32554514
|
| [10] |
Chen M, Jiang M, Wang X, et al. Envafolimab-first PD-1/PD-L1 antibody to be administered by subcutaneous injection for microsatellite instability-high or deficient mismatch repair advanced solid tumors[J]. Expert Opin Biol Ther, 2022, 22(10): 1227-1232. DOI: 10.1080/14712598.2022.2125799.
|
| [11] |
焦盼盼, 薛丽娟, 詹娟. 免疫检查点抑制剂相关不良反应的危险因素与预测因素[J]. 国际肿瘤学杂志, 2023, 50(12): 739-744 DOI: 10.3760/cma.j.cn371439-20230810-00139.
|
| [12] |
Ay S, Atcı MM, Arıkan R, et al. FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer[J]. J Chemother, 2022, 34(7): 465-471. DOI: 10.1080/1120009x.2022.2026125.
|
| [13] |
Choi YJ, Byun Y, Kang JS, et al. Comparison of clinical outcomes of borderline resectable pancreatic cancer according to the neoadjuvant chemo-regimens: gemcitabine versus FOLFIRINOX[J]. Gut Liver, 2021, 15(3): 466-475. DOI: 10.5009/gnl20070.
|
| [14] |
田悦, 肖辛瑶, 李玉峰, 等. 白蛋白结合型紫杉醇联合吉西他滨治疗晚期转移性胰腺癌的疗效和安全性[J]. 中国临床研究, 2023, 36(9): 1291-1296. DOI: 10.13429/j.cnki.cjcr.2023.09.003.
|
| [15] |
Tomášek J. Gemcitabine/nab-paclitaxel in first line treatment of advanced pancreatic cancer-head-to-head comparison with the mFOLFIRINOX regimen[J]. Klin Onkol, 2024, 37(5): 331-334. DOI: 10.48095/ccko2024331.
|
| [16] |
Minz AP, Mohapatra D, Dutta M, et al. Statins abrogate gemcitabine-induced PD-L1 expression in pancreatic cancer-associated fibroblasts and cancer cells with improved therapeutic outcome[J]. Cancer Immunol Immunother, 2023, 72(12): 4261-4278. DOI: 10.1007/s00262-023-03562-9.
pmid: 37926727
|
| [17] |
Li J, Deng Y, Zhang W, et al. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors[J]. J Hematol Oncol, 2021, 14(1): 95. DOI: 10.1186/s13045-021-01095-1.
|
| [18] |
Lawlor RT, Mattiolo P, Mafficini A, et al. Tumor mutational burden as a potential biomarker for immunotherapy in pancreatic cancer: systematic review and still-open questions[J]. Cancers (Basel), 2021, 13(13): 3119. DOI: 10.3390/cancers13133119.
|
| [19] |
Wang J, Yang J, Narang A, et al. Consensus, debate, and prospective on pancreatic cancer treatments[J]. J Hematol Oncol, 2024, 17(1): 92. DOI: 10.1186/s13045-024-01613-x.
|
| [20] |
Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study[J]. Lancet Oncol, 2020, 21(10): 1353-1365. DOI: 10.1016/s1470-2045(20)30445-9.
pmid: 32919526
|
